Open Access: View PDF

DOI: http://dx.doi.org/10.21088/jcms.2454.7123.4118.5

Abstract

Background: Diabetes mellitus has been regarded as an independent risk factor for the progression of coronary artery disease. Even with DES, however patients with diabetes had increased rates of restenosis compared with patients who did not have diabetes. This study aimed to examine individual safety and efficacy endpoints. Methods: A total of 287 patients having chronic stable coronary artery disease or ACS were enrolled. To compare PES and LES in the Diabetic and Non-diabetic population, we separated patients in two groups. Results: In present study, there were 287 patients undergoing PTCA in whom 371 lesions were treated using either PES or LES. Out of 371, 169 lesions were treated with PES and 202 were treated with LES. In those treated with PES, 51 were diabetic while those treated with LES, 66 were diabetic. In present study, among all patients cardiac death, MI, ST, ISR and TLR noted in 2.95%, 4.14%, 2.95%, 5.91% and 4.14% patients respectively in those treated with PES. While those treated with LES cardiac death, MI, ST, ISR and TLR noted in 0.99%, 1.48%, 1.48%, 0.49% and 0.99% patients respectively. ISR and overall MACE observed were statistically significant between two groups. Conclusion: Although diabetes remains a significant predictor of adverse clinical outcomes after percutaneous coronary intervention with DES; in present study there was no statistically significant difference for occurrence of MACE among diabetic and nondiabetic patients. The principle end points of interest occurred with statistically significant lower incidence in patients treated with LES as compared to PES.

 

 

Keywords : Diabetes; Non-Diabetes; Limus Eluting Stent; Paclitaxel Eluting Stent. 

Corresponding Author : Pooja Vyas, Assiastant Professor, Department of Cardiology, U.N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.